Drugs / rgp120
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00000832 | ? → Jan 1998 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rgp120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000832 ↗ |
| Known as | BIOCINE | “Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE)” NCT00000832 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Envelope Protein” NCT00000832 ↗ |
| Route | Intramuscular | “Healthy volunteers receive intramuscular injections of rgp120/HIV-1SF2 with MF59 adjuvant emulsion or MF59 alone at months 0, 1, 6, 9, 10 and 12” NCT00000832 ↗ |